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REVIEW
Abstract: Fixed combination psychotropics, such as a combination of a tricyclic and a typical
antipsychotic, were widely prescribed a generation ago. These products were plagued by a
number of problems, including serious side effects, which caused them to fall out of favor.
More recently, a fixed combination of the atypical antipsychotic olanzapine and the serotonin
selective reuptake inhibitor (SSRI) fluoxetine has been approved in the US for the treatment
of bipolar I depression. Although the combination produced a robust clinical response relative
to placebo or olanzapine alone, the response from practitioners has been mixed. The reasons
for this are likely to be varied. Some practitioners who remember the earlier era of fixed
combinations may simply be resistant to using products of this type. Moreover, the two
constituents are available and many clinicians prescribe them independently. Finally, adverse
events associated with olanzapine may make practitioners hesitant. For example, weight gain
is a common side effect with olanzapine, and may be associated with hyperlipidemia or type
II diabetes. Aggressive management of this problem appears to be helpful in preventing or
reversing weight gain. It is not clear how weight gain is going to impact the uptake of this
effective treatment.
Keywords: combination, atypical, antipsychotic, antidepressant, bipolar disorder, depression,
weight
Introduction
Fixed combinations of drugs are common in medicine and, at one time, were common
in psychiatry. A generation ago, a combination of antidepressants with either
antipsychotics (eg, amitriptyline plus perphenazine [Etrafon
™, Triavil™]) or
benzodiazepines (eg, amitriptyline plus chlordiazepoxide [Limbitrol
™]) were widely
used by both psychiatrists and other medical practitioners. Several basic problems
arose: although these combinations contained antidepressants, the dose in each capsule
was small, eg, 10–25 mg. of amitriptyline. Thus, the vast majority of patients were
substantially underdosed for depression. Unfortunately, many patients overdosed
with these lethal combinations of drugs or committed suicide by other means. In
effect, an insufficient dose of drug was given to treat depression, but a lethal quantity
was prescribed.
In addition, many patients who were prescribed the antidepressant–antipsychotic
combinations did not carry a psychotic diagnosis. Regrettably, exposure to the older,
“typical” or “conventional” antipsychotics resulted in countless cases of tardive
dyskinesia (TD), a permanent syndrome of abnormal involuntary movements
involving the face, limbs, and trunk. This is a disfiguring and, at times, disabling
consequence. Therefore, using these combinations added a completely unnecessary
risk. These preparations were plagued by side effects and other untoward outcomes
such as falls or motor vehicle accidents. These fixed combinations fell out of favor
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by the early 1980s and were seldom used. In fact, a
generation of psychiatrists has been trained with the specter
of fixed combination therapies producing unnecessary risks
without additional benefits above their component
compounds, generating a situation in which practitioners
have resisted using combination drugs.
Against this backdrop a fixed combination of the
antipsychotic drug olanzapine and the antidepressant
fluoxetine (Symbiax
™) has been introduced in the US for
the treatment of bipolar depression. This review is intended
to summarize the data supporting this introduction.
Olanzapine and fluoxetine:
pharmacology
Fluoxetine is a relatively selective serotonin reuptake
inhibitor, with an inhibition constant (Ki) for the serotonin
transporter at ~2.0 nmol/L as opposed to the affinity for the
norepinephrine transporter at > 400 nmol/L (Owens et al
1997). There is a single active metabolite, norfluoxetine,
which also is serotonin transporter selective. Fluoxetine and
the metabolite each have very long half-lives, yielding an
effective half-life of > 50 hours (Lemberger et al 1985).
Olanzapine is a member of a group of antipsychotic
drugs referred to as “novel” or “atypical”. The term
“atypical” refers to the therapeutic profile of these agents
against the classical antipsychotics such as chlorpromazine
and haloperidol. This large group of drugs differ significantly
from the older medications based on a dissociation of their
therapeutic effects from extrapyramidal (Parkinsonian) side
effects. Older, “typical” antipsychotics achieved their
therapeutic effect predominantly via dopamine-2 (D2)
receptor blockade. Hence, therapeutic potency, derived from
D2 receptor blockade in the mesolimbic dopamine
pathways, was directly proportional to D2 receptor blockade
in the striatum, which produced extrapyramidal symptoms.
The atypicals, on the other hand, are weak D2 antagonists;
this is particularly true of the prototypical drug of the class,
clozapine (Meltzer 1991).
However, these drugs produce adequate and, perhaps,
superior antipsychotic effects without potent D2 receptor
blockade. Olanzapine is a modestly potent D2 antagonist
(Ki = 11 nmol/L); however, like other drugs of the class, it
is a significantly more robust blocker of serotonin (5-HT)
2A (5-HT2A) receptors (Ki = 2.5), which is though to be
part of the basis for a superiority of typicals (Bymaster,
Calligaro, et al 1996; Bymaster, Hemrick-Luecke, et al
1996). However, olanzapine also binds inhibits 5-HT2C, 5-
HT3, 5-HT8, as well as norepinephrine (NE) alpha1,
muscarinic cholinergic, histamine1, and glutaminergic
receptors. However, relatively weak D2 coupled with more
potent 5-HT2A antagonism seems to contribute the
enhanced therapeutic effects (Meltzer 1991; Meltzer et al
1989, 2003). The modest D2 binding can be thought of as
competitively inhibiting the binding of dopamine, rather than
following high saturation kinetics. This has been referred
to as a “modulatory” role, antagonizing high levels of
dopamine transmission without fully blocking the receptor.
This property, along with the binding to 5-HT receptors,
may yield improved effects on the cognitive, mood, and
negative symptoms associated with schizophrenia (Tollefson
and Sanger 1999; Meltzer et al 2003). These properties may
be responsible for the unique interaction of olanzapine with
the serotonin selective reuptake inhibitor (SSRI) fluoxetine.
In a study designed to test the interaction between
fluoxetine and olanzapine, rats were administered the
antipsychotic drugs olanzapine, clozapine, risperidone, or
haloperidol, or the 5-HT2A antagonist MDL 100,907, with
and without the SSRIs fluoxetine and sertraline. Olanzapine,
risperidone, clozapine, and fluoxetine (but not haloperidol
or MDL 100,907) given alone, modestly raised
norepinephrine and dopamine levels (mean increases of
133%–194% baseline). Combining olanzapine or risperi-
done with fluoxetine substantially increased dopamine and
norepinephrine levels; olanzapine: norepinephrine = 260%,
dopamine = 332%; risperidone: norepinephrine = 200%,
dopamine = 255%, although this was not seen with
clozapine, haloperidol, or MDL 100,907. Increasing frontal
and nucleus accumbens norepinephrine and dopamine has
been an hypothesized mechanism for the enhanced
antidepressant effects of the combination (Shelton 2003).
Olanzapine plus fluoxetine in
treatment-resistant unipolar
major depression
An early paper reported that the combination of risperidone
(another atypical antipsychotic) given openly with SSRIs
was beneficial for 8 patients with unipolar major depression
who were unresponsive to an SSRI alone (Ostroff and
Nelson 1999). This was followed by a relatively small
double-blind, placebo-controlled trial of the combination
of olanzapine and fluoxetine in non-psychotic, non-bipolar
depressed patients who had not experienced adequate
response to a trial of an SSRI (Shelton et al 2001). Initially,
these patients were treated openly with up to 60 mg/day of
fluoxetine; those who experienced a ≥ 30% improvement
in depression were excluded from a subsequent double-blindTherapeutics and Clinical Risk Management 2006:2(2) 189
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phase. Patients were randomized to receive olanzapine plus
placebo (n = 8), continuation fluoxetine plus placebo
(n = 10), or olanzapine plus fluoxetine (n = 10). The
combined treatment resulted in a robust significant
improvement by the end of the first week that was sustained
through the entire 8-week double blind period. By contrast,
continuation fluoxetine produced no additional effect and
olanzapine alone resulted in an effect over the first three
weeks with a relapse back to baseline depression; the latter
effect has been attributed to the interaction between
olanzapine and the falling plasma levels of fluoxetine and
norfluoxetine, given their long half-lives (Shelton et al
2001).
Two subsequent large scale attempts to replicate this
finding have resulted in failed trials. The initial run-in period
was done with nortriptyline in one study (Shelton et al 2005)
and venlafaxine in the other (Dube et al 2002), followed by
a double-blind phase that included a continuation of the run-
in drug, fluoxetine alone, olanzapine alone, and the
combined treatment. In both studies, combined olanzapine
and fluoxetine produced the same robust response, but the
other groups produced an equivalent effect by the end of
the double-blind period. Because the groups treated with
the run-in medication produced a full response by the end
of this period indicates that they did not include truly
treatment-resistant patients. As well, the mean doses of both
fluoxetine and olanzapine were lower than in the previous
trial. Given these failed trials, further studies will be needed
to determine if this combination is indeed effective in
treatment-resistant unipolar depression.
Olanzapine and fluoxetine in
bipolar depression
Subsequent to the small-scale olanzapine-fluoxetine study
noted earlier (Shelton et al 2001), a large (n = 833) double-
blind, placebo-controlled trial was conducted to compare
olanzapine alone, combined olanzapine and fluoxetine, and
placebo in bipolar I depression. Patients were assigned to
receive olanzapine plus placebo, olanzapine plus fluoxetine,
or placebo alone. The dose of olanzapine alone ranged
between 5 mg/day to 20 mg/day (mean 9.7) and the
olanzapine–fluoxetine was given in fixed combinations of
6/25, 6/50, 12/25, and 12/50 mg/day (mean 7.4/39.3) (Tohen,
Vieta, et al 2003). The doses of the combination were derived
from the mean olanzapine (~12 mg/day) and fluoxetine
(50 mg/day) doses in the earlier study in treatment-resistant
patients. Both olanzapine alone and the combination were
statistically superior to placebo on the main outcome
variable, the Montgomery-Åsberg Depression Rating Scale;
mixed effects random regression model (MMRM) analysis
p < 0.002, all weeks. However, the combined condition
produced a significantly better response than the
monotherapy; MMRM p < 0.02, weeks 4–8. Of significance
is that olanzapine given singly yielded effects predominantly
in vegetative symptoms (eg, sleep and appetite), whereas
the combination was more effective on “core symptoms” of
depression such as depressed mood and negative thinking.
Both olanzapine and the combination showed significant
differences in change from baseline to endpoint on the
Hamilton Anxiety Scale (Hamilton 1959), the Clinical
Global Impressions Scale for Bipolar Disorder, and the
Young Mania Rating Scale (Young et al 1978), although
the scores on the latter were very low in all groups. This
single trial served as the basis of the approval by the US
Food and Drug Administration of combined olanzapine and
fluoxetine for bipolar depression (Symbiax).
Olanzapine has been shown to be effective for acute
mania (Tohen et al 2002) as well as producing long-term
mood stabilizing effects (Tohen et al 2002, 2005; Tohen,
Ketter, et al 2003; Baker et al 2004). One concern about the
combination is that the addition of an antidepressant could
counteract the long term prevention of mania or depression,
given the apparent propensity of antidepressants to induce
cycling in bipolar patients. However, longer-term data
suggest that the combination is no more likely to induce
mania or depression as are olanzapine alone or placebo
(Keck et al 2005).
A renaissance of combination
psychotropics?
Combined olanzapine–fluoxetine represents the first fixed-
dose combination psychotropic treatment approved in the
US for many years. Early uptake has been limited at best,
and a number of factors seem to be limiting its use. As noted
earlier, there may be an inherent resistance among
psychiatrists to using combination psychotropics because
of the history of negative experiences with combined
treatments. However, concerns about adverse effects with
olanzapine, whether given alone or in combination with
fluoxetine, seem to predominate.
The side effect profile of the combination is consistent
with that of olanzapine and fluoxetine, and includes asthenia,
somnolence, tremor, diarrhea, dry mouth, increased appetite,
and weight gain. In spite of a relatively low affinity for D2
receptors and limited problems with extrapyramidal side
effects, olanzapine has been shown to significantly elevateTherapeutics and Clinical Risk Management 2006:2(2) 190
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prolactin, which may cause sexual dysfunction,
osteoporosis, amenorrhea, gynecomastia, or galactorrhea
(Saito et al 2004; Melkersson 2005). Tardive dyskinesia is
a syndrome of abnormal involuntary movements induced
by long-term use of D2 receptor blocking agents (eg,
chlorpromazine). These movements involve the mouth, face,
neck, trunk, or extremities, and can be disfiguring or
debilitating. The rates of TD with all the atypical
antipsychotics are low, but finite at less than 1%. However,
any risk can be problematic given the availability of mood
stabilizing drugs other than the antipsychotics.
The most salient concerns among practitioners, however,
have been weight gain, elevated lipids, and type II diabetes
with olanzapine (Newcomer 2005). The use of olanzapine
has dropped sharply in the recent past, and the acceptance
of the olanzapine–fluoxetine (Symbiax) combination has
been modest. A number of strategies have been investigated
for the control of weight gain. These include standard weight
management methods (eg, diet and exercise counseling)
(Ball et al 2001; Evans et al 2005). Furthermore, several
drugs have been tried to reduce the weight gain problems.
These include the putative appetite suppressing anti-
convulsants topiramate (Levy et al 2003) or sibutramine
(Henderson et al 2005), the histamine-2 antagonists (eg,
nizatidine) (Cavazzoni et al 2003), or the selective
norepinephrine uptake inhibitor reboxetine (Poyurovsky et
al 2003). Although reboxetine is not available in the US,
similarly acting drugs are available (eg, atomoxetine).
Assertive weight management from the start of treatment is
recommended. Moreover, weight should be monitored and
waist circumference measurements can be used (Straker et
al 2005). As well, blood lipids should be measured routinely.
A suggested schedule would be 3, 6, and 12 months, and
biannually thereafter (Baptista et al 2002; Chue and Kovacs
et al 2003).
The potential for long-term antidepressant use to
exacerbate bipolar disorder may affect the use of this fixed
combination, in spite of the fact that both short- (Tohen,
Vieta, et al 2003) and longer-term data do not support this
concern. As well, the availability of other treatments,
including alternative atypical antipsychotics, without weight
gain problems has exacerbated this issue (Seemuller et al
2005). Although the data in bipolar disorder with other
atypical drugs are more limited, practitioners have tended
to select more weight neutral compounds. Treatments such
as lamotrigine (Bowden et al 1999; Calabrese et al 1999)
and lithium (Nemeroff et al 2001) also are often used, even
though the data also are limited. It remains unclear whether
the effect is limited to fluoxetine, or if other if other serotonin
uptake inhibitors may be equally effective. In particular,
practitioners have the option of adding olanzapine to another
antidepressant and not switch to Symbiax. Finally,
practitioners may not prefer to be limited to the available
dosage combinations, even though they provide considerable
flexibility.
Is this a renaissance of fixed combination psychotropics?
Given its robust effect, Symbiax is an important alternative
for bipolar depression, an extremely difficult-to-treat
condition. Alternatively, uptake of the product has been
limited, which is likely to be the result of a variety of issues.
It remains to be seen whether this or any other fixed
combination will become an important part of clinical
practice in the future.
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